Media ReleasesSUDA Pharmaceuticals

View All SUDA Pharmaceuticals News

SUDA Pharmaceuticals - Quarterly Appendix 4C and Activities Report

SUDA Pharmaceuticals Ltd (ASX: SUD), a biotechnology company focused on developing therapies to treat cancer and conditions that affect the central nervous system, today released its Appendix 4C for the fourth quarter of FY 2021.

Cash receipts for the quarter were $68,000 with a bank balance of $6.717m at 30 June. The net outflow from operating activities for the quarter was $0.909m.

In accordance with Listing Rule 4.7C, payments made to related parties and their associates included in item 6.1 of the Appendix 4C incorporates directors’ fees, remuneration and superannuation at commercial rates.

For more information, download the attached PDF.

Download this document

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.